Fit for a fracture.
Seymour
Hannah M
HM
Department of Geriatric Medicine, Royal Perth Hospital, GPO Box X2213, Perth, WA 6000, Australia. Hannah.Seymour@health.wa.gov.au
Glendenning
Paul
P
D000927:Anticonvulsants / Q000009:adverse effects*; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy; D004872:Ergocalciferols / Q000627:therapeutic use; D005260:Female; D005265:Femoral Neck Fractures / Q000209:etiology* / Q000601:surgery; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000209:etiology* / Q000601:surgery; D006801:Humans; D001523:Mental Disorders / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000150:complications; D010634:Phenobarbital / Q000009:adverse effects; D010672:Phenytoin / Q000009:adverse effects; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood; D014808:Vitamin D Deficiency / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy
D000927:Anticonvulsants; D004872:Ergocalciferols; D014807:Vitamin D; D014635:Valproic Acid; D010672:Phenytoin; C104450:25-hydroxyvitamin D; D010634:Phenobarbital